Vaishalee P Kenkre
Affiliation: University of Wisconsin
- The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathwaysVaishalee P Kenkre
University of Wisconsin, Madison, WI 53705, USA
Curr Hematol Malig Rep 7:216-20. 2012..This article discusses the rationale for targeting these pathways and summarizes the current clinical trial data for agents targeting Syk, BTK, and PI3K...
- Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology NetworkVaishalee P Kenkre
Department of Medicine, University of Wisconsin, Madison, WI, USA
Leuk Lymphoma 52:1675-80. 2011..No late toxicities were noted in our cohort. These long-term results suggest that the modified R-hyperCVAD regimen with maintenance rituximab is an excellent option for older patients with newly diagnosed mantle cell lymphoma...
- Follicular lymphoma: emerging therapeutic strategiesVaishalee P Kenkre
Department of Medicine, Division of Hematology Oncology, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, University of Wisconsin, 1111 Highland Avenue, 4059 WIMR, Madison, WI 53705, USA
Expert Rev Hematol 3:485-95. 2010..Finally, hematopoietic stem cell transplantation (both autologous and allogeneic) remains a useful treatment strategy, although the optimal timing of such approaches requires further clarification...
- What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma?Vaishalee P Kenkre
Division of Hematology Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, and the UW Carbone Cancer Center, Madison, WI 53705, USA
Cancer J 18:383-9. 2012..The goals of this review were to provide a framework for decision making and review the literature supporting the various options...